parkinsons-disease-therapeutics-market

Parkinson’s Disease Therapeutics Market By Drug Class (Dopamine Agonists, Levodopa/ Caxrbidopa, Anticholinergic Drugs, Monoamine Oxidase B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT) Inhibitors and Adenosine A2 Receptor Antagonist), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Growth, Future Prospects and Competitive Analysis, 2024 – 2032

25 Mar 2018 Format PDF icon PPT icon XLS icon Request Sample

Parkinson’s disease (PD), is progressive nervous system disorders, characterized by tremor, rigidity, bradykinesia, and postural instability. It is estimated that, the global Parkinson’s disease therapeutics market will show significant market growth over the forecast period from 2023 to 2030. Some key factors that drive PD therapeutics market growth are large unmet needs, projected launch of prominent pipeline drugs (APL-130277, Accordion Pill, P2B-001, ND0612H etc.), increase in research and development activities for development of novel PD therapeutics and growing incidence of PD.  

The report titled “Parkinson’s Disease Therapeutics Market – Growth, Future Prospects and Competitive Analysis, 2023 – 2030” covers detailed analysis of PD therapeutics market for period from 2020 to 2030. For the purpose of comprehensive study of PD therapeutics, this market is segmented on the basis of major drug classes such as dopamine agonists, levodopa/ caxrbidopa, anticholinergic drugs, monoamine oxidase B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors and adenosine A2 receptor antagonist.

To provide detail information regarding geographical market trends and future market prospect geographically, the global PD therapeutics market is classified on the basis of main regional markets such as North America, Europe, Latin America, Asia Pacific and Middle East and Africa. For country level analysis, PD therapeutics market is classified into United States, Canada, Germany, United Kingdom, rest of Europe, Brazil, Mexico, Rest of Latin America, Japan, China, rest of Asia Pacific, GCC and rest of Middle East and Africa.   

This report includes information regarding the current market trends and future market scenario for PD therapeutics; while presenting statistical data along with qualitative information. For better understanding about the ongoing trends of PD therapeutics market and future market projections, exhaustive information about the market opportunities, drivers and challenges in global PD therapeutics market are included in report. For further understanding about the R&D study and their impact on future market scenario, pipeline analysis is included in this report with detailed analysis and market estimation provided for phase 3 drugs. To provide insight on the important players involved in global PD therapeutics market, competitive landscape, and company profiles sections are included in this report.

Parkinson’s disease (PD) is disorder of the nervous system that affects movement; it progresses gradually and sometimes starts with a noticeable tremor. Drugs that increase the dopamine level and those that control non-motor symptoms are used for management of PD. Currently, dopamine receptor agonists such as pramipexole, ropinirole, Bromocriptine, rotigotine, apomorphine etc. preferably used in market; as alone or in combination with levodopa/ carbidopa. Dopamine agonists are not as potent as levodopa and cause less dyskinesias. Levodopa couples with decarboxylase inhibitor drug - carbidopa remains the standard treatment for Parkinson’s disease, which shows fewer advarese effect in short term use. Newly approved drugs such as nouriast and preregistration phase drugs such as CVT-301 expected to drive significant market growth during forecast period. Furthermore, late stage pipeline drugs such as APL-130277, Accordion Pill, P2B-001, ND0612H etc. would facilitate market growth in the coming years.

According to the World Health Organization (WHO), PD is a universal disorder, with a crude incidence rate of 4.5 to 19 per 100,000 population per year. According to the Parkinson's Disease Foundation, PD affects about 1 million people in the United States and more than 4 million people worldwide. About 60,000 people are diagnosed each year in the United States. Among the considered geographical markets, North America is dominating the PD therapeutics market owing to some key factors such as higher target population pool, developed healthcare infrastructure, early diagnosis of disease, extensive research and development for novel drugs, and wide accessibility for novel therapeutics. Asia Pacific is set to capture significant position in coming years on account of improving healthcare infrastructure, rising treatment awareness among the general population, growing incidence of PD. Asia Pacific is base to enormous population pool that is continually growing, thus there is a corresponding increase in incidence of PD that would further lead to increase demand of PD therapeutics.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Parkinson’s Disease Therapeutics market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Parkinson’s Disease Therapeutics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

ATTRIBUTE DETAILS
Research Period  2022-2032
Base Year 2023
Forecast Period  2024-2032
Historical Year  2022
Unit  USD Million
Segmentation
Drug Class
  • Dopamine Agonists
  • Levodopa/ Carbidopa
  • Anticholinergic Drugs
  • Monoamine Oxidase B (MAO-B) Inhibitors
  • Catechol-O-Methyltransferase (COMT) Inhibitors
  • Adenosine A2 Receptor Antagonist
  • Pipeline Candidates: Overview
    •     Phase III (Market estimations by 2026)
      •         APL-130277 (Cynapsus Therapeutics-Sunovion)
      •         Accordion Pill Carbidopa/Levodopa (Intec Pharma)
      •         P2B-001 (Pharma Two B)
      •         ND0612H (Neuroderm)
    •     Phase II & I (Tabular Information)

Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

 Region Segment (2022-2032; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Parkinson’s Disease Therapeutics market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2032.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Parkinson’s Disease Therapeutics market?
  • Which is the largest regional market for Parkinson’s Disease Therapeutics market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Parkinson’s Disease Therapeutics market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Parkinson’s Disease Therapeutics market worldwide?
Choose Licence Type
$4325
$6325
$12650
Why Acute
View Other Reports